141 related articles for article (PubMed ID: 36261691)
21. Piperine, a Bioactive Component of Pepper Spice Exerts Therapeutic Effects on Androgen Dependent and Androgen Independent Prostate Cancer Cells.
Samykutty A; Shetty AV; Dakshinamoorthy G; Bartik MM; Johnson GL; Webb B; Zheng G; Chen A; Kalyanasundaram R; Munirathinam G
PLoS One; 2013; 8(6):e65889. PubMed ID: 23824300
[TBL] [Abstract][Full Text] [Related]
22. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM
Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046
[TBL] [Abstract][Full Text] [Related]
23. Down-regulation of calcium/calmodulin-dependent protein kinase kinase 2 by androgen deprivation induces castration-resistant prostate cancer.
Shima T; Mizokami A; Miyagi T; Kawai K; Izumi K; Kumaki M; Ofude M; Zhang J; Keller ET; Namiki M
Prostate; 2012 Dec; 72(16):1789-801. PubMed ID: 22549914
[TBL] [Abstract][Full Text] [Related]
24. Oncolytic targeting of androgen-sensitive prostate tumor by the respiratory syncytial virus (RSV): consequences of deficient interferon-dependent antiviral defense.
Echchgadda I; Chang TH; Sabbah A; Bakri I; Ikeno Y; Hubbard GB; Chatterjee B; Bose S
BMC Cancer; 2011 Jan; 11():43. PubMed ID: 21276246
[TBL] [Abstract][Full Text] [Related]
25. The role of sLZIP in cyclin D3-mediated negative regulation of androgen receptor transactivation and its involvement in prostate cancer.
Kim Y; Kim J; Jang SW; Ko J
Oncogene; 2015 Jan; 34(2):226-36. PubMed ID: 24441043
[TBL] [Abstract][Full Text] [Related]
26. Improving the Selectivity of PACE4 Inhibitors through Modifications of the P1 Residue.
Dianati V; Navals P; Couture F; Desjardins R; Dame A; Kwiatkowska A; Day R; Dory YL
J Med Chem; 2018 Dec; 61(24):11250-11260. PubMed ID: 30501188
[TBL] [Abstract][Full Text] [Related]
27. Preclinical efficacy of growth hormone-releasing hormone antagonists for androgen-dependent and castration-resistant human prostate cancer.
Fahrenholtz CD; Rick FG; Garcia MI; Zarandi M; Cai RZ; Block NL; Schally AV; Burnstein KL
Proc Natl Acad Sci U S A; 2014 Jan; 111(3):1084-9. PubMed ID: 24395797
[TBL] [Abstract][Full Text] [Related]
28. NF-kappaB2/p52 enhances androgen-independent growth of human LNCaP cells via protection from apoptotic cell death and cell cycle arrest induced by androgen-deprivation.
Nadiminty N; Chun JY; Lou W; Lin X; Gao AC
Prostate; 2008 Dec; 68(16):1725-33. PubMed ID: 18781579
[TBL] [Abstract][Full Text] [Related]
29. Androgen suppresses proliferation of castration-resistant LNCaP 104-R2 prostate cancer cells through androgen receptor, Skp2, and c-Myc.
Chuu CP; Kokontis JM; Hiipakka RA; Fukuchi J; Lin HP; Lin CY; Huo C; Su LC; Liao S
Cancer Sci; 2011 Nov; 102(11):2022-8. PubMed ID: 21781227
[TBL] [Abstract][Full Text] [Related]
30. Heparin-binding epidermal growth factor-like growth factor stimulates androgen-independent prostate tumor growth and antagonizes androgen receptor function.
Adam RM; Kim J; Lin J; Orsola A; Zhuang L; Rice DC; Freeman MR
Endocrinology; 2002 Dec; 143(12):4599-608. PubMed ID: 12446587
[TBL] [Abstract][Full Text] [Related]
31. The prostatic environment suppresses growth of androgen-independent prostate cancer xenografts: an effect influenced by testosterone.
Jennbacken K; Gustavsson H; Tesan T; Horn M; Vallbo C; Welén K; Damber JE
Prostate; 2009 Aug; 69(11):1164-75. PubMed ID: 19399749
[TBL] [Abstract][Full Text] [Related]
32. Increasing C-Terminal Hydrophobicity Improves the Cell Permeability and Antiproliferative Activity of PACE4 Inhibitors against Prostate Cancer Cell Lines.
Dianati V; Kwiatkowska A; Couture F; Desjardins R; Dory YL; Day R
J Med Chem; 2018 Sep; 61(18):8457-8467. PubMed ID: 30180568
[TBL] [Abstract][Full Text] [Related]
33. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA).
Lee SO; Yeon Chun J; Nadiminty N; Trump DL; Ip C; Dong Y; Gao AC
Prostate; 2006 Jul; 66(10):1070-5. PubMed ID: 16637076
[TBL] [Abstract][Full Text] [Related]
34. Difference in protein expression profile and chemotherapy drugs response of different progression stages of LNCaP sublines and other human prostate cancer cells.
Lin HP; Lin CY; Hsiao PH; Wang HD; Jiang SS; Hsu JM; Jim WT; Chen M; Kung HJ; Chuu CP
PLoS One; 2013; 8(12):e82625. PubMed ID: 24349321
[TBL] [Abstract][Full Text] [Related]
35. Overexpression of lysine-specific demethylase 1 promotes androgen-independent transition of human prostate cancer LNCaP cells through activation of the AR signaling pathway and suppression of the p53 signaling pathway.
Li X; Li T; Chen D; Zhang P; Song Y; Zhu H; Xiao Y; Xing Y
Oncol Rep; 2016 Jan; 35(1):584-92. PubMed ID: 26534764
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of tumor growth and progression of LNCaP prostate cancer cells in athymic mice by androgen and liver X receptor agonist.
Chuu CP; Hiipakka RA; Kokontis JM; Fukuchi J; Chen RY; Liao S
Cancer Res; 2006 Jul; 66(13):6482-6. PubMed ID: 16818617
[TBL] [Abstract][Full Text] [Related]
37. [(14)C]Fluciclovine (alias anti-[(14)C]FACBC) uptake and ASCT2 expression in castration-resistant prostate cancer cells.
Ono M; Oka S; Okudaira H; Nakanishi T; Mizokami A; Kobayashi M; Schuster DM; Goodman MM; Shirakami Y; Kawai K
Nucl Med Biol; 2015 Nov; 42(11):887-92. PubMed ID: 26278491
[TBL] [Abstract][Full Text] [Related]
38. Androgens suppress EZH2 expression via retinoblastoma (RB) and p130-dependent pathways: a potential mechanism of androgen-refractory progression of prostate cancer.
Bohrer LR; Chen S; Hallstrom TC; Huang H
Endocrinology; 2010 Nov; 151(11):5136-45. PubMed ID: 20881251
[TBL] [Abstract][Full Text] [Related]
39. Subtilisin-like proprotein convertase paired basic amino acid-cleaving enzyme 4 is required for chondrogenic differentiation in ATDC5 cells.
Yuasa K; Futamatsu G; Kawano T; Muroshita M; Kageyama Y; Taichi H; Ishikawa H; Nagahama M; Matsuda Y; Tsuji A
FEBS J; 2012 Nov; 279(21):3997-4009. PubMed ID: 22925071
[TBL] [Abstract][Full Text] [Related]
40. Multi-Leu PACE4 Inhibitor Retention within Cells Is PACE4 Dependent and a Prerequisite for Antiproliferative Activity.
Couture F; Ly K; Levesque C; Kwiatkowska A; Ait-Mohand S; Desjardins R; Guérin B; Day R
Biomed Res Int; 2015; 2015():824014. PubMed ID: 26114115
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
